We advised the representatives of the several underwriters on the IPO

Davis Polk advised the representatives of the several underwriters in connection with the $381 million initial public offering of 21,177,600 shares of common stock of Eikon Therapeutics, Inc. at $18.00 per share. The common stock is listed on the Nasdaq Global Select Market under the ticker symbol “EIKN.”

Eikon Therapeutics is a late-stage clinical biopharmaceutical company dedicated to building a global, fully integrated organization developing important, innovative medicines to address serious unmet medical needs. The company’s focus is oncology, where it is advancing a pipeline of drug candidates targeting areas of high unmet need in large indications that could eventually become critical medicines in the treatment paradigm of various cancers.

The Davis Polk corporate team included partners Alan F. Denenberg and Emily Roberts and associates Savannah J. Dowling and Hannah R. Carter. Partner David R. Bauer and associates Gabrielle Mazero and Anne Kim provided intellectual property advice. The tax team included counsel Yixuan Long and associate Omar Hersi. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post